Drugs facing NCE-1 in 2029

1. Avmapki Fakzynja Co-pack (copackaged) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7897792 VERASTEM INC Coumarin derivative having antitumor activity
Feb, 2027

(1 year, 6 months from now)

US8247411 VERASTEM INC Sulfonyl amide derivatives for the treatment of abnormal cell growth
Apr, 2028

(2 years from now)

US7928109 VERASTEM INC Sulfonyl amide derivatives for the treatment of abnormal cell growth
Aug, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11400090 VERASTEM INC Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder
Oct, 2038

(13 years from now)

US11517573 VERASTEM INC Therapeutic compositions, combinations, and methods of use
Sep, 2040

(15 years from now)

US11873296 VERASTEM INC Solid forms of a dual RAF/MEK inhibitor
Dec, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 08, 2030

Drugs and Companies using AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE ingredient

NCE-1 date: 08 May, 2029

Market Authorisation Date: 08 May, 2025

Treatment: Treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy, in combination with defactinib; Treatment of adult patients wi...

Dosage: CAPSULE, TABLET

More Information on Dosage

AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) family patents

Family Patents

2. Gomekli patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11066358 SPRINGWORKS Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
Feb, 2041

(15 years from now)

US11084780 SPRINGWORKS Door construction
Feb, 2041

(15 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12295925 SPRINGWORKS Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
Feb, 2041

(15 years from now)

US11819487 SPRINGWORKS Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
Feb, 2041

(15 years from now)

US11806321 SPRINGWORKS Non-linear dosing of mirdametinib
Feb, 2041

(15 years from now)

US11453641 SPRINGWORKS Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
Feb, 2041

(15 years from now)

US12263146 SPRINGWORKS Non-linear dosing of mirdametinib
Feb, 2041

(15 years from now)

US12011424 SPRINGWORKS Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib
Feb, 2041

(15 years from now)

US12090128 SPRINGWORKS Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof
Feb, 2041

(15 years from now)

US12037306 SPRINGWORKS Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
Feb, 2041

(15 years from now)

US12275688 SPRINGWORKS Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
Feb, 2041

(15 years from now)

US11571402 SPRINGWORKS Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof
Feb, 2041

(15 years from now)

US12220390 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US12324791 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US11883375 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US12257215 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US11806322 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US11839595 SPRINGWORKS Mirdametinib treatment
Mar, 2043

(17 years from now)

US12029711 SPRINGWORKS Dosage forms of mirdametinib
Mar, 2044

(18 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 11, 2030
Orphan Drug Exclusivity(ODE-488) Feb 11, 2032

Drugs and Companies using MIRDAMETINIB ingredient

NCE-1 date: 11 February, 2029

Market Authorisation Date: 11 February, 2025

Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection

Dosage: CAPSULE

More Information on Dosage

GOMEKLI family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Grafapex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7199162 MEDEXUS Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
Mar, 2026

(7 months from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 21, 2030
Orphan Drug Exclusivity(ODE-513) Jan 21, 2032
Orphan Drug Exclusivity(ODE-514) Jan 21, 2032

Drugs and Companies using TREOSULFAN ingredient

NCE-1 date: 21 January, 2029

Market Authorisation Date: 21 January, 2025

Treatment: Administering treosulfan as a preparative regimen for allogeneic stem cell transplantation

Dosage: POWDER

More Information on Dosage

GRAFAPEX family patents

Family Patents

4. Ibtrozi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9187489 NUVATION Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Jun, 2033

(7 years from now)

US9751887 NUVATION Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
Jun, 2033

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 11, 2030

Drugs and Companies using TALETRECTINIB ADIPATE ingredient

NCE-1 date: 11 June, 2029

Market Authorisation Date: 11 June, 2025

Treatment: Treatment of patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)

Dosage: CAPSULE

More Information on Dosage

IBTROZI family patents

Family Patents

5. Journavx patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11834441 VERTEX PHARMS INC Substituted tetrahydrofurans as modulators of sodium channels
Dec, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2030

Drugs and Companies using SUZETRIGINE ingredient

NCE-1 date: 30 January, 2029

Market Authorisation Date: 30 January, 2025

Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine

Dosage: TABLET

More Information on Dosage

JOURNAVX family patents

Family Patents

6. Qfitlia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9376680 GENZYME CORP Serpinc1 iRNA compositions and methods of use thereof
Mar, 2033

(7 years from now)

US9127274 GENZYME CORP Serpinc1 iRNA compositions and methods of use thereof
Mar, 2033

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091759 GENZYME CORP Methods and compositions for treating a Serpinc1-associated disorder
Dec, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 28, 2030
Orphan Drug Exclusivity(ODE-510) Mar 28, 2032
Orphan Drug Exclusivity(ODE-511) Mar 28, 2032

Drugs and Companies using FITUSIRAN SODIUM ingredient

NCE-1 date: 28 March, 2029

Market Authorisation Date: 28 March, 2025

Treatment: Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia a or b with or without factor viii or ix inhibitors

Dosage: SOLUTION

More Information on Dosage

QFITLIA family patents

Family Patents

7. Romvimza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9181223 DECIPHERA PHARMS 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
Mar, 2034

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12285430 DECIPHERA PHARMS Methods of treating disorders using CSF1R inhibitors
Dec, 2039

(14 years from now)

US11103507 DECIPHERA PHARMS Methods of treating disorders using CSF1R inhibitors
Feb, 2040

(14 years from now)

US11679110 DECIPHERA PHARMS Methods of treating disorders using CSF1R inhibitors
Feb, 2040

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 14, 2030

Drugs and Companies using VIMSELTINIB ingredient

NCE-1 date: 14 February, 2029

Market Authorisation Date: 14 February, 2025

Treatment: Treatment of tenosynovial giant cell tumor

Dosage: CAPSULE

More Information on Dosage

ROMVIMZA family patents

Family Patents

8. Tryptyr patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9433679 ALCON LABS INC Use of TRMP8 for treating opthalmic diseases or conditions involving tearing
Sep, 2031

(6 years from now)

US10028920 ALCON LABS INC Methods for treating occular irritation involving tearing by administering modulators of TRPM8
Sep, 2031

(6 years from now)

US9095609 ALCON LABS INC Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia
Sep, 2031

(6 years from now)

US11850221 ALCON LABS INC Ophthalmic pharmaceutical compositions and uses thereof
Dec, 2042

(17 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 28, 2030

Drugs and Companies using ACOLTREMON ingredient

NCE-1 date: 28 May, 2029

Market Authorisation Date: 28 May, 2025

Treatment: Treatment of the signs and symptoms of dry eye disease (ded)

Dosage: SOLUTION/DROPS

More Information on Dosage

TRYPTYR family patents

Family Patents

9. Vanrafia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623819 NOVARTIS Therapy for complications of diabetes
Aug, 2028

(3 years from now)

US11874283 NOVARTIS Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
Feb, 2032

(6 years from now)

US10016393 NOVARTIS Stabilized pharmaceutical dosage forms comprising atrasentan
Jul, 2034

(8 years from now)

US9364458 NOVARTIS Stabilized pharmaceutical dosage forms comprising atrasentan
Jul, 2034

(8 years from now)

US12121509 NOVARTIS Methods of improving renal function
Dec, 2040

(15 years from now)

US11998526 NOVARTIS Methods of improving renal function
Dec, 2040

(15 years from now)

US11491137 NOVARTIS Methods of improving renal function
Dec, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 02, 2030

Drugs and Companies using ATRASENTAN HYDROCHLORIDE ingredient

NCE-1 date: 02 April, 2029

Market Authorisation Date: 02 April, 2025

Treatment: Treatment of primary immunoglobulin a nephropathy (igan)

Dosage: TABLET

More Information on Dosage

VANRAFIA family patents

Family Patents